Ethereum treasury company Propanc Biopharma reaches up to $100 million strategic financing agreement with Hexstone Capital
ChainCatcher reported that Propanc Biopharma, a biopharmaceutical company adopting an Ethereum treasury strategy, has announced a strategic financing agreement with family office Hexstone Capital for up to $100 million. Propanc CEO James Nathanielsz stated that this financing will accelerate the development of the company’s clinical pipeline, and they plan to grow the value of their digital asset treasury to $100 million or more within the next 12 months.
Hexstone Capital has previously invested in several companies with digital asset treasuries, involving BTC, ETH, SOL, DOGE, and other digital assets. According to previous reports, in early September Propanc Biopharma announced plans to acquire $100 million worth of Ethereum.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US President Donald Trump says was ready to strike Houthis in Yemen, then pulled back
ZAMA gains traction as 24h trading volume surges
Global economy risks fragmentation! Australia bets on AI as a new growth engine
In a potentially more fragmented and unpredictable global economy over the next 40 years, Australia relies on the deployment and development of artificial intelligence (AI) to drive economic growth.
Europe’s aviation fuel “red alert” in the fourth quarter: Shortfall will reach 510,000 barrels/day, South Korea’s exports surge to a four-year high to urgently fill the gap
According to analysts and shipping data, Europe will face a supply gap for aviation fuel in the fourth quarter, even as it turns to distant suppliers such as South Korea. South Korea's aviation fuel exports to Europe in September are set to reach a four-year high.
Crypto prices
More
